• Timothy K Cronin, Cian Ronayne, Niamh O'Donovan, Eimear McGuinness, Katie Cooke, Maeve Dennehy, Colum Dennehy, Derek G Power, Mary R Cahill, Dearbhaile C Collins, Roisin M Connolly, Richard M Bambury, Vitaliy Mykytiv, Michaela J Higgins, Sinéad A Noonan, and Seamus O'Reilly.
• School of Medicine and Health, University College Cork, Cork, Ireland. 114349821@umail.ucc.ie.
• Ir J Med Sci. 2024 Oct 1; 193 (5): 217121772171-2177.

BackgroundExpanded access programs (EAPs) allow cancer patients with unmet clinical need to obtain access to pre-authorisation treatments. There is no standardised process for implementing these programs nationally, and real-world data on their impact is lacking.AimsThis study aimed to evaluate the prevalence of such EAPs and their impact in a cancer centre.MethodsData relating to adult cancer patients treated via EAPs from 2011 to 2021 in three Cork university hospitals was collated. Descriptive statistics were employed to get an overview of the impact these programs currently have on cancer care provision.ResultsWe identified 193 patients who accessed EAPs during the study period, availing of 33 separate drugs for a total of 50 different cancer indications. The prevalence of EAP usage was shown to have been trending upwards in recent years with a total of 189 programs being accessed throughout the period. Drugs provided were from a number of different anti-cancer drug classes, particularly targeted therapies (n = 18) and immune checkpoint inhibitors (n = 17). Cancers from a wide range of both solid and liquid tumour types were treated with EAP drugs, and patients treated were from across a broad spectrum of ages (26-82, SD 11.99).ConclusionsEAPs have an increasing role in accessing novel cancer therapies in our community and by extension nationally. Equity of EAP access would be facilitated by a national registry of available agents which we have established. Assessment of their benefits and toxicities would be enhanced by the requirement for a real-world database as a condition of EAP approval.© 2024. The Author(s).

20 keywords...

hide…